1. Home
  2. |Insights
  3. |Sweeping U.S. Patent Law Changes - America Invents Act

Sweeping U.S. Patent Law Changes - America Invents Act

Client Alert | 2 min read | 09.22.11

On September 16, 2011, the America Invents Act was signed into law by the President. The Act includes significant changes to U.S. patent law, which are summarized below. Some of these changes are effective immediately, while others will become effective over the next several years.

First-to-File System

  • The U.S. is changing from a first-to-invent system to a first-inventor-to-file system.
  • There will be a one-year grace period limited to public disclosures made by the inventor or others who obtained the information from the inventor.
  • Interferences will no longer exist; instead, derivation proceedings will be used to determine whether an invention was derived from another inventor.

Third-Party Pre-Issuance Submissions

  • A third party may submit a patent, a published patent application, or a printed publication to the U.S.P.T.O. during prosecution for consideration by the Examiner.

Post-Grant Procedures

  • A third party may request post-grant review within nine months of the issuance of a patent. The request may be based on any ground of invalidity.
  • A patentee may request supplemental examination to protect against inequitable conduct.
  • There will be several changes to inter partes reexamination, including replacing the substantial new question of patentability threshold for instituting a reexamination with a showing that the requester is reasonably likely to prevail with respect to at least one claim.
  • District court review of ex parte reexamination decisions under 35 U.S.C. § 145 is eliminated.

Litigation

  • The best-mode defense can no longer be raised in a litigation. However, disclosing the best mode is still required to obtain a patent.
  • Failing to obtain or present an opinion of counsel may not be used to prove willfulness or inducement to infringe.
  • The prior-use defense is expanded beyond business method claims. The prior commercial use must be in the U.S. at least one year before the earlier of the effective filing date or the date of disclosure of the claimed invention.
  • The joinder of unrelated accused infringers is limited.
  • False marking lawsuits are limited, and virtual marking is allowed.
  • Venue for some lawsuits against the U.S.P.T.O. is changed from Washington D.C. to the Eastern District of Virginia.

U.S.P.T.O. Fees

  • Effective on September 26, 2011, there will be a 15% surcharge on general statutory fees and maintenance fees.
  • There is a 75% reduction in fees for "micro entities."
  • There will be a $4800 fee for prioritized examination, and a $400 fee for applications that are not filed electronically.

Additional Provisions

  • The issuance of claims directed to or encompassing a human organism is barred.
  • Strategies for reducing, avoiding, or deferring tax liability are deemed to be in the prior art.
  • An assignee or a person with a sufficient proprietary interest in an invention will be able to apply for a patent. The applicant may file a "substitute statement" instead of an inventor's oath when the inventor cannot be reached or refuses to make the oath.

Crowell & Moring will be evaluating the implementation of these provisions as they become effective. Please let us know if you would like more details on how these new provisions may affect your U.S. patent practices.

Insights

Client Alert | 5 min read | 12.12.25

Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality

On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument....